ArticleEpilepsia2025
Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Disrupted temperature-sleep coupling mechanism in a Dravet syndrome mouse model.Nature communications · 2026Article
- Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome.Epilepsia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivePatients with drug-resistant epilepsy, including Dravet syndrome, are frequently prescribed multiple antiseizure medications. Nevertheless, people with Dravet syndrome often have inadequate seizure control, and there is an ongoing unmet clinical need to identify novel therapeutics. As a proof-of-principle study to further validate and characterize the Scn1a
methodsFollowing a 14-day treatment, we evaluated the efficacy of stiripentol add-on to clobazam and valproic acid using hyperthermia-induced (n = 6) and video-electroencephalography (EEG) monitoring of spontaneous seizure tests (n = 13). Valproic acid was delivered via osmotic minipump, whereas stiripentol and clobazam were administered via food pellets delivered through automatic feeders. Bioanalytical assays were performed to evaluate drug concentrations in plasma and brain using liquid chromatography-tandem mass spectrometry.
resultsStiripentol, clobazam, N-desmethylclobazam, and valproic acid all yielded plasma concentrations within the therapeutic plasma concentration range for humans. Stiripentol added to clobazam and valproic acid significantly elevated the seizing temperatures in the hyperthermia-induced seizure assay (**p = 0.0018; Log-rank test). Clobazam, valproic acid, and stiripentol co-administration significantly reduced spontaneous seizure frequency compared to clobazam and valproic acid combined (***p = 0.0003, Mann-Whitney test). SIGNIFICANCE: This research lays the groundwork for exploring effective add-on compounds to clobazam and valproic acid in treating Dravet syndrome. The study further highlights the utility of the Scn1a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.